TG Therapeutics, Inc.
https://www.tgtherapeutics.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TG Therapeutics, Inc.
Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens
Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.
Lilly Inks Follow-Up Radiopharmaceuticals Deal With Aktis
The big pharma will pay $60m upfront and make an equity investment in the Boston-based startup.
Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh
Plus transactions involving Sanofi/Fulcrum, Reneo/OnKure, Lilly/Mitsubishi Tanabe, Lantern/Oregon, Zydus/Eiger and more.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Ariston Pharmaceuticals, Inc.
- Atlantic Pharmaceuticals, Inc.
- Atlantic Technology Ventures, Inc.
- Manhattan Pharmaceuticals, Inc.
- Manhattan Research Development, Inc.
- Tarpan Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TG Therapeutics, Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice